EAST WINDSOR, N.J. — Aurobindo has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application for amoxicillin and clavulanate potassium for oral suspension USP, 125 mg/31.25 mg per 5 mL and 250 mg/62.5 mg per 5 mL. Aurobindo’s amoxicillin and clavulanate potassium for oral suspension is an AB-rated generic equivalent to the reference listed drug, Neopharma’s Augmentin.

Amoxicillin and clavulanate potassium for oral suspension USP is a combination penicillin-class antibacterial and beta-lactamase inhibitor indicated for treatment of the following:

• Lower respiratory tract infections
• Acute bacterial otitis media
• Sinusitis
• Skin and skin structure infections
• Urinary tract infections